Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$9MCash on Hand
17.3mo Cash Runway
Follow SNGX by emailGet an email when SNGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SNGX, unsubscribe in one click. Privacy
📣 What SNGX Says Is Next
in 2026 · “With these results, we intend to embark on a reformulation of SGX945 to enable home-based treatment and look forward to interacting with the health authorities in designing a follow-on placebo-controlled Phase 2b study in 2026.”
Company press release, Feb 12, 2026 · SEC filing
second half of 2026 · “Top-line results from the actively enrolling 80 patient confirmatory Phase 3 FLASH 2 ( F luorescent L ight A nd S ynthetic H ypericin 2 ) clinical trial for HyBryte™ (SGX301 or synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL) are expected in the second half of 2026, with an interim analysis fast approaching in 2Q.”
Company press release, Feb 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Earnings Soligenix filed its Q3 2026 10-Q as a prospectus supplement for 408,640 shares underlying previously issued warrants. Net loss was $1,117,525 for the quarter and cash was $9,023,510 at September 30, 2026. Form 424B3 · SEC filing
Nov 6, 2026 ·
Earnings Soligenix filed its Q3 2026 10-Q as a prospectus supplement covering 4,253 shares underlying previously issued warrants. Net loss was $1,117,525 for the quarter and $5,929,844 year to date; cash was $9,023,510 at September 30, 2026. Form 424B3 · SEC filing
Nov 6, 2026 ·
Financing Soligenix filed its Q3 2026 10-Q as a prospectus supplement for resale of up to 1,054,688 shares from warrant exercises. Net loss was $1,117,525 for the quarter and $5,929,844 for nine months, with cash of $9,023,510 at September 30, 2026. Form 424B3 · SEC filing
Nov 6, 2026 ·
Financing Filed Prospectus Supplement No. 3 to resell 5,330,560 shares underlying previously issued common warrants, attaching the Q3 2026 10-Q. Nine-month net loss was $5,929,844; cash and equivalents were $9,023,510 at September 30, 2026. Form 424B3 · SEC filing
Sep 21, 2026 ·
Shareholder vote Shareholders approved a reverse stock split at a 1-for-2 to 1-for-20 ratio, to be set by the board within one year, and raised authorized common shares from 75,000,000 to 125,000,000. All five director nominees were elected, and an annual say-on-pay vote will now be held every year. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Oct 2025 · Phase 2 · Results Expected · Topical SGX302 for Mild-to-Moderate Psoriasis Registry primary completion date, not a results date
May 2025 · Phase 2 · Results Expected · Dusquetide for the Treatment of Behcet's Disease Registry primary completion date, not a results date
May 2024 · Phase 2 · Results Expected · HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL Registry primary completion date, not a results date
Aug 2022 · Phase 2 · Results Expected · PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma Registry primary completion date, not a results date
Jun 2020 · Phase 3 · Results Expected · DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer Registry primary completion date, not a results date
Jun 2020 · Phase 3 · Results Expected · FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not SNGX's own candidates): Mechlorethamine Hydrochloride.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
SNGX holds $9M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.6M/quarter from operations,
an estimated runway of 17.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:68 · High
Cash runway 17 months +18
ATM program on file since Jun 2026 +15
Going-concern doubt in the latest 10-Q +15However, as of the date of this filing, the Company continues to explore various strategic alternatives but has not consummated any transaction or obtained any additional program assets to develop, which raises substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count 23,368,754 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SNGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.